Background:The role of different genotypes in nucleos(t)ide analogs(NAs)treatment is still debated.Previous studies conducted on special populations evidenced that the E genotype had the lower virological and serologi...Background:The role of different genotypes in nucleos(t)ide analogs(NAs)treatment is still debated.Previous studies conducted on special populations evidenced that the E genotype had the lower virological and serological response.This descriptive study aims to recognize the hepatitis B“s”antigen(HBsAg)decline during tenofovir disoproxil fumarate(TDF)treatment in a cohort of patient affected by chronic hepatitis B(CHB).Methods:We retrospectively included all patients with CHB treated with TDF between April 2007 and March 2012 with a duration of treatment of 7 years.Kinetics of HBsAg was determined as serological response in this cohort.We include 110 subjects;virological response was observed in all subjects with genotypes A,B,and D;in 17 patients with C genotype(94.4%)and 24 with E genotype(96%).HBeAg loss was observed in 2 patients with genotype A(50%),3 with B(100%),0 with C(0%),1 with D(20%),and 1 with E genotype(25%).Results:In multivariate analysis we observed as predictive factors of HBsAg decline the baseline level of HBsAg(OR=1.467;95%CI:1.221–5.113;p=0.017)and viral genotypes(OR=11.218;95%CI:5.441–41.138;p<0.001).Conclusion:This study confirmed higher HBsAg decline after 7 years of treatment in A and B genotypes,and lower in C,E,and D genotypes.However,no evidence is enough to choose a single NAs,but in special populations,as well as in genotype E,the use of TDF should be preferred to entecavir.展开更多
文摘Background:The role of different genotypes in nucleos(t)ide analogs(NAs)treatment is still debated.Previous studies conducted on special populations evidenced that the E genotype had the lower virological and serological response.This descriptive study aims to recognize the hepatitis B“s”antigen(HBsAg)decline during tenofovir disoproxil fumarate(TDF)treatment in a cohort of patient affected by chronic hepatitis B(CHB).Methods:We retrospectively included all patients with CHB treated with TDF between April 2007 and March 2012 with a duration of treatment of 7 years.Kinetics of HBsAg was determined as serological response in this cohort.We include 110 subjects;virological response was observed in all subjects with genotypes A,B,and D;in 17 patients with C genotype(94.4%)and 24 with E genotype(96%).HBeAg loss was observed in 2 patients with genotype A(50%),3 with B(100%),0 with C(0%),1 with D(20%),and 1 with E genotype(25%).Results:In multivariate analysis we observed as predictive factors of HBsAg decline the baseline level of HBsAg(OR=1.467;95%CI:1.221–5.113;p=0.017)and viral genotypes(OR=11.218;95%CI:5.441–41.138;p<0.001).Conclusion:This study confirmed higher HBsAg decline after 7 years of treatment in A and B genotypes,and lower in C,E,and D genotypes.However,no evidence is enough to choose a single NAs,but in special populations,as well as in genotype E,the use of TDF should be preferred to entecavir.
